14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      In vivo quantification of neurofibrillary tangles with [ 18F]MK-6240

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Imaging agents capable of quantifying the brain’s tau aggregates will allow a more precise staging of Alzheimer’s disease (AD). The aim of the present study was to examine the in vitro properties as well as the in vivo kinetics, using gold standard methods, of the novel positron emission tomography (PET) tau imaging agent [ 18F]MK-6240.

          Methods

          In vitro properties of [ 18F]MK-6240 were estimated with autoradiography in postmortem brain tissues of 14 subjects (seven AD patients and seven age-matched controls). In vivo quantification of [ 18F]MK-6240 binding was performed in 16 subjects (four AD patients, three mild cognitive impairment patients, six healthy elderly individuals, and three healthy young individuals) who underwent 180-min dynamic scans; six subjects had arterial sampling for metabolite correction. Simplified approaches for [ 18F]MK-6240 quantification were validated using full kinetic modeling with metabolite-corrected arterial input function. All participants also underwent amyloid-PET and structural magnetic resonance imaging.

          Results

          In vitro [ 18F]MK-6240 uptake was higher in AD patients than in age-matched controls in brain regions expected to contain tangles such as the hippocampus, whereas no difference was found in the cerebellar gray matter. In vivo, [ 18F]MK-6240 displayed favorable kinetics with rapid brain delivery and washout. The cerebellar gray matter had low binding across individuals, showing potential for use as a reference region. A reversible two-tissue compartment model well described the time–activity curves across individuals and brain regions. Distribution volume ratios using the plasma input and standardized uptake value ratios (SUVRs) calculated after the binding approached equilibrium (90 min) were correlated and higher in mild cognitive impairment or AD dementia patients than in controls. Reliability analysis revealed robust SUVRs calculated from 90 to 110 min, while earlier time points provided inaccurate estimates.

          Conclusions

          This evaluation shows an [ 18F]MK-6240 distribution in concordance with postmortem studies and that simplified quantitative approaches such as the SUVR offer valid estimates of neurofibrillary tangle load 90 min post injection. [ 18F]MK-6240 is a promising tau tracer with the potential to be applied in the disease diagnosis and assessment of therapeutic interventions.

          Related collections

          Most cited references39

          • Record: found
          • Abstract: found
          • Article: not found

          A new look at the statistical model identification

          IEEE Transactions on Automatic Control, 19(6), 716-723
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

            The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all-cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia. Copyright © 2011. Published by Elsevier Inc.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Neuropathological stageing of Alzheimer-related changes

              Eighty-three brains obtained at autopsy from nondemented and demented individuals were examined for extracellular amyloid deposits and intraneuronal neurofibrillary changes. The distribution pattern and packing density of amyloid deposits turned out to be of limited significance for differentiation of neuropathological stages. Neurofibrillary changes occurred in the form of neuritic plaques, neurofibrillary tangles and neuropil threads. The distribution of neuritic plaques varied widely not only within architectonic units but also from one individual to another. Neurofibrillary tangles and neuropil threads, in contrast, exhibited a characteristic distribution pattern permitting the differentiation of six stages. The first two stages were characterized by an either mild or severe alteration of the transentorhinal layer Pre-alpha (transentorhinal stages I-II). The two forms of limbic stages (stages III-IV) were marked by a conspicuous affection of layer Pre-alpha in both transentorhinal region and proper entorhinal cortex. In addition, there was mild involvement of the first Ammon's horn sector. The hallmark of the two isocortical stages (stages V-VI) was the destruction of virtually all isocortical association areas. The investigation showed that recognition of the six stages required qualitative evaluation of only a few key preparations.
                Bookmark

                Author and article information

                Contributors
                tharick.alipascoal@mail.mcgill.ca
                monica.shin@mail.mcgill.ca
                peter.ms.kang@gmail.com
                mira.chamoun@mail.mcgill.ca
                daniel.chartrand@mcgill.ca
                sulantha.s@gmail.com
                idriss.bennacef@merck.com
                joseph.therriault1@gmail.com
                kokpin22@gmail.com
                robert.hopewell@mcgill.ca
                reda.bouhachi2@mcgill.ca
                chris.hsiao@mcgill.ca
                andrea.lessa@gmail.com
                jean-paul.soucy@mcgill.ca
                gassan.massarweh@mcgill.ca
                serge.gauthier@mcgill.ca
                (+1) 514-761-6131 , pedro.rosa@mcgill.ca
                Journal
                Alzheimers Res Ther
                Alzheimers Res Ther
                Alzheimer's Research & Therapy
                BioMed Central (London )
                1758-9193
                31 July 2018
                31 July 2018
                2018
                : 10
                : 74
                Affiliations
                [1 ]ISNI 0000 0004 1936 8649, GRID grid.14709.3b, Translational Neuroimaging Laboratory, , The McGill University Research Centre for Studies in Aging, ; 6825 LaSalle Boulevard, Verdun, QC H4H 1R3 Canada
                [2 ]ISNI 0000 0004 0646 3639, GRID grid.416102.0, Montreal Neurological Institute, ; 3801 University Street, Montreal, QC H3A 2B4 Canada
                [3 ]ISNI 0000 0001 2260 0793, GRID grid.417993.1, Translational Biomarkers, Merck & Co., Inc., ; 770 Sumneytown Pike, West Point, PA 19486 USA
                [4 ]ISNI 0000 0004 1936 8649, GRID grid.14709.3b, Douglas Hospital, McGill University, ; 6875 La Salle Blvd—FBC room 3149, Montreal, QC H4H 1R3 Canada
                Article
                402
                10.1186/s13195-018-0402-y
                6069775
                30064520
                b7154ff3-3a41-4e41-bb70-8109b12443ba
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 21 February 2018
                : 6 July 2018
                Funding
                Funded by: CIHR
                Award ID: MOP-11-51-31
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2018

                Neurology
                tau positron emission tomography,neurofibrillary tangles,alzheimer’s disease
                Neurology
                tau positron emission tomography, neurofibrillary tangles, alzheimer’s disease

                Comments

                Comment on this article